Concepedia

Lisa Roberts-Rapp

LR

15

Publications

944

Citations

14

H-Index

2014

Active since

Affiliations

AbbVie (United States)(Current)

Dana-Farber Cancer Institute

Erasmus MC Cancer Institute

Columbia University Irving Medical Center

NorthShore University HealthSystem

Lisa Roberts-Rapp is an author at AbbVie (United States) specializing in medicine, oncology, and cancer therapeutics.

Top concepts

Publications per year

2014–2020

15

Publications

15

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study

Martin J. van den Bent, Hui Gan, Andrew B. Lassman et al. · Cancer Chemotherapy and Pharmacology · 2017 · 130 citations · Full text

MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor

Yu Xiao, Paul Nimmer, George S. Sheppard et al. · Molecular Cancer Therapeutics · 2015 · 120 citations · Full text

, , +15

Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)

Darren C. Phillips, Yu Xiao, Lloyd T. Lam et al. · Blood Cancer Journal · 2015 · 113 citations · Full text

Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma

David A. Reardon, Andrew B. Lassman, Martin J. van den Bent et al. · Neuro-Oncology · 2016 · 110 citations · Full text

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with<i>EGFR</i>-amplified, recurrent glioblastoma: results from an international phase I multicenter trial

Andrew B. Lassman, Martin J. van den Bent, Hui Gan et al. · Neuro-Oncology · 2018 · 94 citations · Full text

Rows per page

1–5 of 15